glp-1 tripeptide GLP-1-based therapies for diabetes, obesity and beyond 1 producing cells in the gut Targeting GLP-1 in the brain
Description
Fatigue or asthenia is recognised as a common adverse reaction for some GLP-1 receptor agonists, as documented in their Summary of Product Characteristics (SmPCs)

Development of curcumin as an epigenetic agent

With generics arriving in 2026, access will expand

B6, B9 B12 , (): , ,
.webp)
10.3390/healthcare11202749

If drinking more water and eating more soluble fiber aren't enough to get things moving, a magnesium supplement may help, says Katz
